Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Phase II Trial Comparing ABI-007 (Abraxane®, Nab®-Paclitaxel) to Taxotere in First Line Therapy of Patients With Stage IV Breast Cancer

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Celgene Corporation
ClinicalTrials.gov Identifier:
NCT00274456
First received: January 10, 2006
Last updated: July 15, 2013
Last verified: July 2013
Results First Received: February 7, 2011  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Condition: Metastatic Breast Cancer
Interventions: Drug: ABI-007
Drug: Docetaxel

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
Three hundred and two patients were enrolled and randomized between November 2005 and June 2006, of which 300 received study drug and were evaluated for response and safety. Data below represents data cut-off 31 March 2008.

Reporting Groups
  Description
ABI-007 300 mg/m^2 q3w ABI-007 300 mg/m^2 administered once every third week (q3w).
ABI-007 100 mg/m^2 Weekly ABI-007 100 mg/m^2 once weekly for 3 weeks followed by 1 week of rest
ABI-007 150 mg/m^2 Weekly ABI-007 150 mg/m^2 once weekly for 3 weeks followed by 1 week of rest
Docetaxel 100 mg/m^2 q3w Docetaxel (Taxotere) 100 mg/m^2 administered once every third week (q3w).

Participant Flow:   Overall Study
    ABI-007 300 mg/m^2 q3w     ABI-007 100 mg/m^2 Weekly     ABI-007 150 mg/m^2 Weekly     Docetaxel 100 mg/m^2 q3w  
STARTED     76     76     74     74  
At Least One Response Assessment     73     76     73     70  
COMPLETED     39 [1]   49 [1]   39 [1]   29 [1]
NOT COMPLETED     37     27     35     45  
Still on treatment                 2                 3                 5                 1  
Unacceptable toxicity                 10                 5                 12                 16  
Adverse Event                 0                 1                 2                 2  
Physician Decision                 7                 5                 6                 13  
Lost to Follow-up                 0                 0                 1                 0  
Withdrawal by Subject                 18                 13                 9                 13  
[1] Treatment completed upon progressive disease



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
ABI-007 300 mg/m^2 q3w ABI-007 300 mg/m^2 administered once every third week (q3w).
ABI-007 100 mg/m^2 Weekly ABI-007 100 mg/m^2 once weekly for 3 weeks followed by 1 week of rest
ABI-007 150 mg/m^2 ABI-007 150 mg/m^2 once weekly for 3 weeks followed by 1 week of rest.
Docetaxel 100 mg/m^2 q3w Docetaxel (Taxotere) 100 mg/m^2 administered once every third week (q3w).
Total Total of all reporting groups

Baseline Measures
    ABI-007 300 mg/m^2 q3w     ABI-007 100 mg/m^2 Weekly     ABI-007 150 mg/m^2     Docetaxel 100 mg/m^2 q3w     Total  
Number of Participants  
[units: participants]
  76     76     74     74     300  
Age  
[units: years]
Mean ± Standard Deviation
  51.7  ± 9.47     55.4  ± 9.59     53.3  ± 9.14     55.4  ± 11.57     53.9  ± 10.05  
Age, Customized  
[units: Participants]
         
>=65 years     9     14     10     19     52  
<65 years     67     62     64     55     248  
Gender  
[units: participants]
         
Female     76     76     74     74     300  
Male     0     0     0     0     0  
Race/Ethnicity, Customized  
[units: Participants]
         
White, Non-Hispanic, Non-Latino     74     75     74     74     297  
White, Hispanic or Latino     2     1     0     0     3  
Weight  
[units: Kg]
Mean ± Standard Deviation
  72.56  ± 12.668     73.64  ± 14.670     76.24  ± 13.437     75.99  ± 14.034     74.59  ± 13.742  
Eastern Cooperative Oncology Group (ECOG) Performance Status [1]
[units: participants]
         
0 (fully active)     34     33     24     28     119  
1 (restrictive but ambulatory)     35     39     45     44     163  
2 (ambulatory but unable to work)     7     4     5     2     18  
3 (limited self-care) + 4 (completely disabled)     0     0     0     0     0  
Menopausal Status  
[units: Participants]
         
Pre-menopausal     26     14     21     12     73  
Post-menopausal     49     62     53     60     224  
Unknown     1     0     0     2     3  
Physician Assessment of Sensory Neuropathy [2]
[units: Participants]
         
Grade 0     67     70     65     67     269  
Grade 1     9     6     9     7     31  
Time from Primary Diagnosis and from First Metastasis/Relapse to Study Entry  
[units: Years]
Median ( Full Range )
         
Time from Primary Diagnosis to Study Entry     1.24  
  ( 0.0 to 11.9 )  
  1.17  
  ( 0.0 to 14.9 )  
  0.97  
  ( 0.0 to 16.9 )  
  1.27  
  ( 0.0 to 14.3 )  
  1.23  
  ( 0.0 to 16.9 )  
Time from First Metastasis/Relapse to Study Entry     0.02  
  ( 0.0 to 8.2 )  
  0.04  
  ( 0.0 to 8.1 )  
  0.05  
  ( 0.0 to 2.0 )  
  0.04  
  ( 0.0 to 2.6 )  
  0.04  
  ( 0.0 to 8.2 )  
Current Site of Metastasis/Relapse [3]
[units: Participants]
         
Breast     10     10     11     11     42  
Skin/Soft Tissue     16     18     15     19     68  
Supraclavicular     23     25     20     25     93  
Axilla     43     48     47     44     182  
Lung/Thoracic     53     49     51     58     211  
Hepatic/Liver     21     28     23     25     97  
Abdomen/Peritoneal     12     11     4     7     34  
Pelvis     0     1     2     1     4  
Bone     22     25     33     25     105  
Other     1     4     1     1     7  
Dominant Current Site of Metastasis/Relapse  
[units: Participants]
         
Visceral     64     61     59     67     251  
Non-visceral     12     15     15     7     49  
Stage at Primary Diagnosis [4]
[units: participants]
         
Stage I     2     4     3     2     11  
Stage IIa     11     13     11     13     48  
Stage IIb     12     7     13     15     47  
Stage IIIa     11     10     7     6     34  
Stage IIIb     14     14     9     13     50  
Stage IIIc     0     2     0     1     3  
Stage IV     23     25     28     21     97  
Unknown     3     1     3     3     10  
Number of Lesions (Target + Non-Target) [5]
[units: Participants]
         
0 lesions     0     0     0     0     0  
1 lesion     2     1     1     4     8  
2-3 lesions     11     13     6     10     40  
>3 lesions     63     62     67     60     252  
[1] A scale used to assess the progress of disease in a patient, how the disease affects the daily living abilities of the patient, and determine appropriate treatment and prognosis.
[2] The physician assessed sensory neuropathy using the National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI CTCAE) of “Neurology -- Neuropathy – Sensory”. The scale is 0=normal and 1=asymptomatic; loss of deep tendon reflexes or paresthesia (including tingling) but not interfering with function.
[3] Patients may have multiple sites of metastasis/relapse.
[4]

Invasive breast cancer stages:

  • Stage I-cancer cells are breaking through to or invading normal surrounding breast tissue.
  • Stage IIa-breast tumor about 2cm and involvement of ancillary lymph nodes.
  • Stage IIb-a larger tumor than earlier phases.
  • Stage IIIa-axillary lymph nodes clumping together.
  • Stage IIIb-spread further to the skin, breast bone or chest wall.
  • Stage IIIc-expanded involvement of lymph nodes.
  • Stage IV-cancer that has spread beyond the breast and nearby lymph nodes to other organs of the body.
[5] Target lesions were selected on the basis of their size (those with the longest diameter) and their suitability for accurate repeat measurements (either by imaging techniques or clinically).



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Percentage of Participants Showing an Overall Response As Assessed by the Independent Radiology Reader and by the Investigator   [ Time Frame: Day 1 up to 95 weeks ]

2.  Secondary:   Percentage of Participants With Stable Disease for ≥ 16 Weeks, or Complete or Partial Overall Response   [ Time Frame: Day 1 up to 95 weeks ]

3.  Secondary:   Kaplan-Meier Estimates for Progression-free Survival (PFS)   [ Time Frame: Day 1 up to 95 weeks ]

4.  Secondary:   Kaplan-Meier Estimates for Duration of Response Based on Independent Radiology Assessment of Response and Progression   [ Time Frame: Day 1 - 95 weeks ]

5.  Secondary:   Kaplan-Meier Estimates for Duration of Response Based on Investigator Assessment of Response and Progression   [ Time Frame: Day 1 - 95 weeks ]

6.  Secondary:   Kaplan-Meier Estimate for Overall Survival (OS)   [ Time Frame: Day 1 to 221 weeks ]

7.  Secondary:   Participants With Treatment-Emergent, Treatment-Related Adverse Events   [ Time Frame: Day 1 up to 125 weeks ]

8.  Other Pre-specified:   Nadir of Myelosuppression (Over All Cycles) as Measured by Absolute Neutrophils (ANC), White Blood Cells (WBC) and Platelet Counts   [ Time Frame: Day 1 up to 125 weeks ]

9.  Other Pre-specified:   Nadir of Myelosuppression (Over All Cycles) as Measured by Hemoglobin (Hb) Counts   [ Time Frame: Day 1 up to 125 weeks ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.


Results Point of Contact:  
Name/Title: Associate Director, Clinical Trials Disclosure
Organization: Celgene Corporation
phone: 1-888-260-1599
e-mail: clinicaltrialdisclosure@celgene.com


Publications of Results:

Responsible Party: Celgene Corporation
ClinicalTrials.gov Identifier: NCT00274456     History of Changes
Other Study ID Numbers: CA024
Study First Received: January 10, 2006
Results First Received: February 7, 2011
Last Updated: July 15, 2013
Health Authority: United States: Food and Drug Administration
Ukraine: Ministry of Health